Lilly to Acquire Ventyx Biosciences for Oral Inflammatory Disease Therapies
Eli Lilly is acquiring Ventyx Biosciences in a $1.2 billion all-cash deal to enhance its pipeline of oral therapies targeting inflammation-related diseases across various medical fields, aiming to address high unmet medical needs.